Back to results
US 2022/0008526 A1Published application
Methods and compositions for cancer immunotherapy
AssigneeTorque Therapeutics, Inc.
InventorsThomas Lars Andresen, Douglas Jones, Elena Geretti, Gulzar Ahmad
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for cancer immunotherapy, and more particularly immune cells loaded with protein clusters and/or immunostimulatory fusion molecules (IFMs), in combination with an inhibitor of a checkpoint inhibitor.
Claims18
A composition comprising:
- a nucleated cell loaded with a plurality of protein clusters and/or immunostimulatory fusion molecules (IFMs);
- and
- an inhibitor of a checkpoint inhibitor;
- wherein each protein cluster comprises a plurality of therapeutic protein monomers reversibly cross-linked to one another via a plurality of biodegradable cross-linkers, wherein the protein cluster has a size between 30 nm and 1000 nm in diameter measured by dynamic light scattering, wherein the cross-linker degrades, after administration into a subject in need thereof, under physiological conditions so as to release the therapeutic protein monomers from the protein cluster, wherein optionally the protein cluster further comprises a surface modification such as polycation so as to allow the protein cluster to associate with the nucleated cell;
- wherein each IFM is engineered to contain an immunostimulatory cytokine molecule and a targeting moiety (e.g., an antibody or an antigen-binding fragment thereof) having an affinity to an antigen on the surface of the nucleated cell, wherein the immunostimulatory cytokine molecule is operably linked to targeting moiety.
2 more elements
A method for providing cancer immunotherapy, comprising:
- administering to a patient in need thereof a plurality of nucleated cells loaded with a plurality of protein clusters and/or immunostimulatory fusion molecules (IFMs);
- and
- administering to the patient an inhibitor of a checkpoint inhibitor;
- wherein each protein cluster comprises a plurality of therapeutic protein monomers reversibly cross-linked to one another via a plurality of biodegradable cross-linkers, wherein the protein cluster has a size between 30 nm and 1000 nm in diameter measured by dynamic light scattering, wherein the cross-linker degrades, after administration into a subject in need thereof, under physiological conditions so as to release the therapeutic protein monomers from the protein cluster, wherein optionally the protein cluster further comprises a surface modification such as polycation so as to allow the protein cluster to associate with the nucleated cell;
- wherein each IFM is engineered to contain an immunostimulatory cytokine molecule and a targeting moiety (e.g., an antibody or an antigen-binding fragment thereof) having an affinity to an antigen on the surface of the nucleated cell, wherein the immunostimulatory cytokine molecule is operably linked to targeting moiety.
2 more elements
Dependencies are inferred from the claim text.